4.7 Article

Liquid chromatography with time-of-flight mass spectrometry for simultaneous determination of chemotherapeutant residues in salmon

期刊

ANALYTICA CHIMICA ACTA
卷 562, 期 2, 页码 176-184

出版社

ELSEVIER
DOI: 10.1016/j.aca.2006.01.075

关键词

chemotherapeutant residues; salmon; liquid chromatography; time-of-flight mass spectrometry

向作者/读者索取更多资源

Liquid chromatography with time-of-flight mass spectrometry (LC-TOF-MS) method has been developed for simultaneous confirmation by accurate mass measurement and quantitative determination of antibiotics (enrofloxacin, oxolinic acid, flumequine, erythromycin), fungicides (malachite green MG, leucomalachite green LMG) and parasiticide (emamectin benzoate) residues in edible portion of salmon. Confirmation of chemotherapeutant residues has been based on the system of identification points (IPs) established in the Commission Decision 2002/657/EC concerning the use of mass spectrometry (MS) techniques. A validation study on matrix is presented evaluating accuracy in terms of precision (lambda(ppm) 0.83-1.15) and trueness (0.22-0.70 Da). Limits of detection (LODs) and limits of quantification (LOQs) were in ranges of 1-3 and 3-9 mu g/kg, below the maximum residue limits (MRLs) established in current EU legislation (100-200 mu g/kg) for these chemotherapeutants. Considering the EU guidelines, decision limits (CC alpha) and detection capabilities (CC beta) were determined (ranges of 103-218 and 107-234 mu g/kg, respectively) for authorised substances. For no authorised compounds (MG and LMG), LODs were 2 and 1 mu g/kg, respectively, but exceed the MRPL (minimum required performance limit) established in the legislation which corresponds to the sum of MG and LMG (2 mu g/kg). Acceptable intra-day and inter-day variability, in terms of relative standard deviation (R.S.D.) of the analytical method, were obtained (2-15%). Linearity was demonstrated from the LOQs of the analytes to 600 mu g/kg (r > 0.9991). The method has involved an extraction procedure based on solid-liquid extraction (SLE) with recoveries higher than 80% for most target chemotherapeutants, with exception of enrofloxacin (40%). (c) 2006 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据